These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19572040)

  • 1. Maternal administration of anti-angiogenic agents, TNP-470 and Angiostatin4.5, induces fetal microphthalmia.
    Rutland CS; Jiang K; Soff GA; Mitchell CA
    Mol Vis; 2009 Jun; 15():1260-9. PubMed ID: 19572040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of intrauterine growth restriction by reducing placental vascular growth with the angioinhibin TNP-470.
    Rutland CS; Mukhopadhyay M; Underwood S; Clyde N; Mayhew TM; Mitchell CA
    Biol Reprod; 2005 Dec; 73(6):1164-73. PubMed ID: 16079307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Embryonic vascular disruption adverse outcomes: Linking high throughput signaling signatures with functional consequences.
    Ellis-Hutchings RG; Settivari RS; McCoy AT; Kleinstreuer N; Franzosa J; Knudsen TB; Carney EW
    Reprod Toxicol; 2017 Jun; 70():82-96. PubMed ID: 28527947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombophilic-type placental pathologies and skeletal growth delay following maternal administration of angiostatin4.5 in mice.
    Rutland CS; Atkinson SD; Mukhopadhyay M; Jiang K; Soff GA; Mayhew TM; Mitchell CA
    Biol Reprod; 2011 Mar; 84(3):505-13. PubMed ID: 20980690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells.
    Farinelle S; Malonne H; Chaboteaux C; Decaestecker C; Dedecker R; Gras T; Darro F; Fontaine J; Atassi G; Kiss R
    J Pharmacol Toxicol Methods; 2000; 43(1):15-24. PubMed ID: 11091126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470.
    Gervaz P; Scholl B; Padrun V; Gillet M
    Liver; 2000 Apr; 20(2):108-13. PubMed ID: 10847478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel chemoembolization using calcium-phosphate ceramic microsphere incorporating TNP-470, an anti-angiogenic agent.
    Emoto M; Naganuma Y; Choijamts B; Ohno T; Yoshihisa H; Kanomata N; Kawarabayashi T; Aizawa M
    Cancer Sci; 2010 Apr; 101(4):984-90. PubMed ID: 20109162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad spectrum antiangiogenic treatment for ocular neovascular diseases.
    Benny O; Nakai K; Yoshimura T; Bazinet L; Akula JD; Nakao S; Hafezi-Moghadam A; Panigrahy D; Pakneshan P; D'Amato RJ
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice.
    Beecken WD; Fernandez A; Joussen AM; Achilles EG; Flynn E; Lo KM; Gillies SD; Javaherian K; Folkman J; Shing Y
    J Natl Cancer Inst; 2001 Mar; 93(5):382-7. PubMed ID: 11238700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice.
    Emoto M; Ishiguro M; Iwasaki H; Kikuchi M; Kawarabayashi T
    Gynecol Oncol; 2003 Apr; 89(1):88-94. PubMed ID: 12694659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin.
    Shishido T; Yasoshima T; Denno R; Mukaiya M; Sato N; Hirata K
    Jpn J Cancer Res; 1998 Sep; 89(9):963-9. PubMed ID: 9818033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.
    Hotz HG; Reber HA; Hotz B; Sanghavi PC; Yu T; Foitzik T; Buhr HJ; Hines OJ
    J Gastrointest Surg; 2001; 5(2):131-8. PubMed ID: 11331474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNP-470: an angiogenesis inhibitor in clinical development for cancer.
    Kruger EA; Figg WD
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1383-96. PubMed ID: 11060750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice.
    White HM; Acton AJ; Considine RV
    Obesity (Silver Spring); 2012 Oct; 20(10):2003-9. PubMed ID: 22510957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the angiogenesis inhibitor TNP-470 on murine lymphoma/leukemia cells in vivo and in vitro.
    Norén-Nyström U; Eriksson M; Eriksson B; Roos G; Bergh A; Holmberg D
    Exp Hematol; 2003 Feb; 31(2):143-9. PubMed ID: 12591279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
    Masunaga S; Ono K; Nishimura Y; Kanamori S; Saga T; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y; Hori H
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):799-807. PubMed ID: 10837967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of an anti-angiogenic agent, TNP-470, on the growth of oral squamous cell carcinomas.
    Ueda N; Kamata N; Hayashi E; Yokoyama K; Hoteiya T; Nagayama M
    Oral Oncol; 1999 Nov; 35(6):554-60. PubMed ID: 10705089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
    Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
    Clin Cancer Res; 2002 Jul; 8(7):2389-98. PubMed ID: 12114444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis inhibitor TNP-470 suppresses growth of peritoneal disseminating foci of human colon cancer line Lovo.
    Fan YF; Huang ZH
    World J Gastroenterol; 2002 Oct; 8(5):853-6. PubMed ID: 12378629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNP-470 promotes initial vascular sprouting in xenograft tumors.
    Huang J; Frischer JS; New T; Kim ES; Serur A; Lee A; Kadenhe-Chiwishe A; Pollyea DA; Yokoi A; Holash J; Yancopoulos GD; Kandel JJ; Yamashiro DJ
    Mol Cancer Ther; 2004 Mar; 3(3):335-43. PubMed ID: 15026554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.